Lipopharma is a pioneering clinical-stage biopharmaceutical company that focuses its activities on the discovery, rational design and clinical development of a new generation of medicines that act through the selective regulation of membrane lipids, a novel therapeutic strategy known as “Membrane-Lipid Therapy” (MLT). Lipopharma arose as an academic spin-off, founded to turn new scientific breakthroughs and discoveries made by scientists at the Institute of Health Science Research (IUNICS - part of the University of the Balearic Islands in Mallorca, Spain) into a new class of innovative lipid-regulator therapeutic agents that we believe have dramatic game-changing potential in the treatment of life-threatening conditions like cancer, CNS, inflammatory or metabolic diseases
Palma de Mallorca, November 04th, 2014. Lipopharma presented today at BIO-Europe 2014, the leading biotechnological event in Europe, held in Frankfurt (Germany) 3-5 November, the main highlights of its Phase I/IIA clinical trial with Minerval for the treatment of glioma and other solid tumours. The presentation was in the Next Generation track and the main results of the first 5 cohorts in the MIN-001-1203 study have been presented. No safety issues have arisen at doses of up to 8g/day while two objective responses have been reported, one of then in a GBM patient showing a sustained Partial Response after more than 1 year of continued treatment.
Palma de Mallorca. June 16th, 2014. Lipopharma Scientific Advisory Board (SAB) has held a meeting today in Madrid were a group of leading scientist had discussed the molecular basis and mechanism of action of the novel MLT-based LP226A1, a compound in Lipopharma's pipeline currently in preclinical development as a potential treatment against Alzheimer's Disease (AD). In this meeting, two world renowned scientific experts in lipid science and cell membranes have joined as new members of Lipopharma's SAB: Dr. Nicolson and Dr. Epand.